Abstract
The growing demand for rapid, accurate, and accessible diagnostic tools has driven significant progress in biosensor technologies for medical applications. Our recent research centers on the development of advanced electrochemical and optical biosensors, particularly those built on paper-based and microfluidic platforms tailored for point-of-care diagnostics. In the electrochemical domain, we have engineered a variety of user-friendly and multiplexed devices for the detection of infectious diseases such as hepatitis B and C viruses (HBV, HCV), human immunodeficiency virus (HIV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and Mycobacterium tuberculosis (TB). These sensors integrate nanostructured electrodes, peptide nucleic acid (PNA) probes, G-quadruplex DNAzymes, and amplification-free detection strategies. Combined with microfluidic flow control, wireless circuitry, and smartphone interfaces, the platforms offer portable, rapid, and high-performance diagnostics with minimal sample handling. On the optical front, we have developed colorimetric and fluorescent biosensors for clinically important targets such as human papillomavirus (HPV) DNA, SARS-CoV-2 spike antigen, tuberculosis biomarkers, and cardiovascular indicators like C-reactive protein (CRP). These devices utilize gold nanoparticle-based signal enhancement, electroluminescent transducers, and smartphone-assisted readouts. Design innovations such as delayed lateral flow and enzyme-free amplification further enhance sensitivity without compromising usability. Collectively, our electrochemical and optical biosensors represent a powerful suite of next-generation tools for decentralized medical diagnostics. Their low cost, portability, and clinical relevance position them as promising solutions for real-world applications, particularly in resource-limited environments.